234 related articles for article (PubMed ID: 34353779)
21. Management of hydroxyurea resistant or intolerant polycythemia vera.
Raman I; Pasricha SR; Prince HM; Yannakou CK
Leuk Lymphoma; 2021 Oct; 62(10):2310-2319. PubMed ID: 33949918
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
[TBL] [Abstract][Full Text] [Related]
23. Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life.
Verstovsek S
Clin Adv Hematol Oncol; 2022 Jun; 20 Suppl 11(6):1-12. PubMed ID: 35772008
[No Abstract] [Full Text] [Related]
24. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
25. Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study.
Büyükaşık Y; Ali R; Turgut M; Saydam G; Yavuz AS; Ünal A; Ar MC; Ayyıldız O; Altuntaş F; Okay M; Çiftçiler R; Meletli Ö; Soyer N; Mastanzade M; Güven Z; Soysal T; Karakuş A; Yiğenoğlu TN; Uçar B; Gökçen E; Tuğlular T
Turk J Haematol; 2020 Aug; 37(3):177-185. PubMed ID: 32075363
[TBL] [Abstract][Full Text] [Related]
26. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
27. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.
Verstovsek S; Harrison CN; Kiladjian JJ; Miller C; Naim AB; Paranagama DC; Habr D; Vannucchi AM
Leuk Res; 2017 May; 56():52-59. PubMed ID: 28193568
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Sekhri R; Sadjadian P; Becker T; Kolatzki V; Huenerbein K; Meixner R; Marchi H; Wallmann R; Fuchs C; Griesshammer M; Wille K
Ann Hematol; 2021 Nov; 100(11):2707-2716. PubMed ID: 34462786
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.
Harrison CN; Griesshammer M; Miller C; Masszi T; Passamonti F; Zachee P; Durrant S; Pane F; Guglielmelli P; Verstovsek S; Jones MM; Hunter DS; Sun W; Li J; Khan M; Habr D; Kiladjian JJ
Br J Haematol; 2018 Jul; 182(2):279-284. PubMed ID: 29984424
[No Abstract] [Full Text] [Related]
30. Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?
Spivak JL
Lancet Haematol; 2020 Mar; 7(3):e184-e185. PubMed ID: 31982040
[No Abstract] [Full Text] [Related]
31. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
32. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S; Isfort S; Wolf D; Heidel FH; Hochhaus A; Schafhausen P; Griesshammer M; Wolleschak D; Platzbecker U; Döhner K; Jost PJ; Parmentier S; Schaich M; von Bubnoff N; Stegelmann F; Maurer A; Crysandt M; Gezer D; Kortmann M; Franklin J; Frank J; Hellmich M; Brümmendorf TH;
Ann Hematol; 2023 Feb; 102(2):349-358. PubMed ID: 36564535
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.
Al-Mashdali AF; Kashgary WR; Yassin MA
Medicine (Baltimore); 2021 Nov; 100(44):e27722. PubMed ID: 34871267
[TBL] [Abstract][Full Text] [Related]
35. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Kremyanskaya M; Mascarenhas J; Hoffman R
Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
[TBL] [Abstract][Full Text] [Related]
36. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Parasuraman SV; Shi N; Paranagama DC; Bonafede M
J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
[TBL] [Abstract][Full Text] [Related]
37. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Harrison CN; Mead AJ; Panchal A; Fox S; Yap C; Gbandi E; Houlton A; Alimam S; Ewing J; Wood M; Chen F; Coppell J; Panoskaltsis N; Knapper S; Ali S; Hamblin A; Scherber R; Dueck AC; Cross NCP; Mesa R; McMullin MF
Blood; 2017 Oct; 130(17):1889-1897. PubMed ID: 29074595
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Vaddi K; Verstovsek S; Kiladjian JJ
Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077
[TBL] [Abstract][Full Text] [Related]
39. Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Palandri F; Auteri G; Abruzzese E; Caocci G; Bonifacio M; Mendicino F; Latagliata R; Iurlo A; Branzanti F; Garibaldi B; Trawinska MM; Cattaneo D; Krampera M; Mulas O; Martino EA; Cavo M; Vianelli N; Impera S; Efficace F; Heidel F; Breccia M; Elli EM; Palumbo GA
Ann Hematol; 2024 Jun; 103(6):1931-1940. PubMed ID: 38478023
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?
Beauverd Y; McLornan DP; Radia DH; Harrison CN
Future Oncol; 2016 Mar; 12(6):739-49. PubMed ID: 26846873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]